{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '5.3.2.2', 'NonCR/NonPD', '68', '5.3.2.3', 'Progressive Disease', '69', '5.3.3', 'Evaluation of Time Point Response', '69', '5.4', 'Pharmacokinetic Assessment', '69', '5.5', 'Safety Assessment', '69', '5.5.1', 'Vital Signs', '69', '5.5.2', 'Adverse Events', '69', '5.5.2.1', 'Adverse Events of Possible Hepatic Origin', '69', '5.5.3', 'Laboratory Assessments', '70', '5.5.4', 'Physical Examination', '71', '5.5.5', 'Ophthalmology Examination', '71', '5.5.6', 'Electrocardiogram', '71', '5.6', 'Adverse Events and Other Safety Aspects', '71', '5.6.1', 'Definition of Adverse Events', '71', '5.6.1.1', 'Abnormal Laboratory Findings', '72', '5.6.1.2', 'Potential Cases of Drug-Induced Liver Injury', '72', '5.6.1.3', 'Disease Progression and Study Endpoints', '72', '5.6.2', 'Definition of Serious Adverse Events (SAEs)', '73', '5.6.3', 'Criteria for Causal Relationship to Study Drug', '73', '5.6.4', 'Criteria for Defining the Severity of an Adverse Event', '74', '5.6.5', 'Reporting of Serious Adverse Events', '75', '5.6.6', 'Follow-up of Adverse Events', '77', '5.6.7', 'Monitoring of Common Serious Adverse Events', '77', '5.6.8', 'Special Situations', '77', '5.6.8.1', 'Pregnancy', '78', '5.6.8.2', 'Medication Error, Overdose and \"Off-Label Use\"', '79', '5.6.8.3', 'Misuse/Abuse', '79', '5.6.8.4', 'Occupational Exposure', '79', '5.6.8.5', 'Suspected Drug-Drug Interaction', '79', '5.6.9', 'Supply of New Information Affecting the Conduct of the Study', '80', '5.6.10', 'Deviations from the Protocol and Other Actions Taken to Avoid Life-', 'Threatening Risks to Subjects (Unique to Japan)', '80', '5.7', 'Test Drug Concentration', '81', '5.8', 'Other Measurements, Assessments or Methods', '81', '5.8.1', 'Exploratory Biomarker', '81', '14 Sep 2020', 'Astellas', 'Page 4 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '5.8.2', 'Biomarkers in Blood', '81', '5.8.3', 'Biomarkers in Pre-Treatment Tumor Tissue', '81', '5.8.4', 'Blood Sample for Future Pharmacogenomic Analysis (Retrospective)', '81', '5.8.5', 'EORTC Core Quality of Life Questionnaire, QLQ-C30', '82', '5.8.6', 'EuroQOL-5 Dimensions', '82', '5.8.7', 'Healthcare Resource Utilization (HRU)', '82', '5.9', 'Total Amount of Blood', '82', '6', 'DISCONTINUATION', '83', '6.1', 'Discontinuation of Individual Subject(s)', '83', '6.2', 'Discontinuation of the Site', '84', '6.3', 'Discontinuation of the Study', '84', '7', 'STATISTICAL METHODOLOGY', '85', '7.1', 'Sample Size', '85', '7.2', 'Analysis Sets', '85', '7.2.1', 'Full Analysis Set', '85', '7.2.2', 'Safety Analysis Set', '85', '7.2.3', 'Response Evaluable Set', '85', '7.2.4', 'Pharmacokinetic Analysis Set', '86', '7.3', 'Demographics and Baseline Characteristics', '86', '7.3.1', 'Subject Disposition', '86', '7.3.2', 'Previous and Concomitant Medications', '86', '7.3.3', 'Medical History', '86', '7.4', 'Analysis of Efficacy', '86', '7.4.1', 'Analysis of Primary Endpoint', '87', '7.4.1.1', 'Primary Analysis', '87', '7.4.1.2', 'Sensitivity Analysis', '87', '7.4.2', 'Analysis of Secondary Endpoints', '87', '7.4.2.1', 'Progression Free Survival', '87', '7.4.2.2', 'Overall Response Rate', '88', '7.4.2.3', 'Duration of Response', '88', '7.4.2.4', 'Disease Control Rate (DCR)', '88', '7.4.2.5', 'QOL and PRO Parameters', '88', '7.4.3', 'Subgroup Analysis', '88', '7.4.4', 'Analysis of Exploratory Endpoints', '89', '14 Sep 2020', 'Astellas', 'Page 5 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}